Delaware |
11-2644611
|
(State
or other jurisdiction |
(IRS
Employer |
of
incorporation or organization) |
Identification
No.) |
Contents
|
|
BOVIE
MEDICAL CORPORATION
SEPTEMBER
30, 2004 AND DECEMBER 31, 2003
(UNAUDITED) |
|||||||
Assets |
|||||||
September
30, 2004 |
December
31, 2003(1) |
||||||
Current
assets: |
|||||||
Cash |
$ |
1,771,130 |
$ |
306,137 |
|||
Trade
accounts receivable |
2,298,851 |
1,708,181 |
|||||
Inventories |
2,005,003 |
2,451,149 |
|||||
Prepaid
expenses |
150,993 |
390,025 |
|||||
Deferred
tax asset |
386,200 |
386,200 |
|||||
Total
current assets |
6,612,177 |
5,241,692 |
|||||
Property
and equipment, net |
2,166,281
|
1,900,015
|
|||||
Other
assets: |
|||||||
Repair
parts |
142,203 |
228,226 |
|||||
Trade
name |
1,509,662 |
1,509,662
|
|||||
Patent
rights, net |
102,671 |
144,967
|
|||||
Deposits
|
6,111 |
9,470 |
|||||
Investment
- in unconsolidated affiliate |
200,000 |
200,000
|
|||||
1,960,647 |
2,092,325 |
||||||
$ |
10,739,105
|
$ |
9,234,032 |
||||
(1)Derived
from audited financial statements. |
|||||||
The
accompanying notes are an integral part of the financial
statements. |
|||||||
BOVIE
MEDICAL CORPORATION
CONSOLIDATED
BALANCE SHEET
SEPTEMBER
30, 2004 AND DECEMBER 31, 2003
(UNAUDITED) |
|||||||
Liabilities
and Stockholders' Equity |
|||||||
September
30, 2004 |
December
31, 2003
(1) |
||||||
Current
liabilities: |
|||||||
Accounts
payable |
$ |
770,491 |
$ |
679,792 |
|||
Accrued
expense |
478,673 |
473,630
|
|||||
Deferred
revenue |
159,554 |
103,445
|
|||||
Customer
deposits |
36,000 |
112,000 |
|||||
Current
maturities of long-term debt |
31,668 |
31,668 |
|||||
Total
current liabilities |
1,476,386 |
1,400,535
|
|||||
Long
Term Liabilities |
356,246 |
383,670
|
|||||
Stockholders'
equity: |
|||||||
Preferred
Stock, par value $.001 |
|||||||
10,000,000
shares authorized |
|||||||
0
issued and outstanding |
-- |
-- |
|||||
on
September 30, 2004 and December 31, 2003 |
|||||||
Common
stock par value $.001; 40,000,000 |
|||||||
shares
authorized, issued and outstanding |
|||||||
13,853,628
shares and 13,464,528 shares |
|||||||
on
September 30, 2004 and December 31, |
|||||||
2003
respectively |
20,532 |
16,641 |
|||||
Additional
paid in capital |
20,379,499 |
20,093,936 |
|||||
Accumulated
deficit |
(11,493,558 |
) |
(12,660,750 |
) | |||
Total
stockholders' equity |
8,906,473 |
7,449,827
|
|||||
Total
liabilities and stockholders' |
|||||||
Equity |
$ |
10,739,105
|
$ |
9,234,032 |
|||
(1)Derived
from audited financial statements. |
|||||||
The
accompanying notes are an integral part of the financial
statements. |
|||||||
BOVIE
MEDICAL CORPORATION.
FOR
THE NINE MONTHS ENDED SEPTEMBER 30, 2004 AND 2003
(UNAUDITED) |
|||||||
2004 |
2003 |
||||||
Sales |
$ |
15,629,483 |
$ |
11,996,428 |
|||
Cost
of sales |
9,498,374 |
6,865,911 |
|||||
Gross
profit |
6,131,109 |
5,130,517 |
|||||
Costs
and expenses: |
|||||||
Research
and development |
836,661 |
668,490 |
|||||
Professional
services |
307,717 |
307,500 |
|||||
Salaries
and related costs |
1,346,904 |
1,167,791 |
|||||
Selling,
general and administrative |
2,434,565 |
2,012,709 |
|||||
Equity
in net loss of unconsolidated affiliate |
26,886 |
51,983 |
|||||
4,952,733 |
4,208,473
|
||||||
Gain
(Loss) from operations |
1,178,376 |
922,044 |
|||||
Other
income (expense): |
|||||||
Interest |
(11,185 |
) |
(27,272 |
) | |||
Income |
1,167,191 |
894,772 |
|||||
Provision
for income tax |
(
420,200 |
) |
(313,170 |
) | |||
Realized
benefit of loss carryforward |
420,200 |
313,170 |
|||||
Net
income from continuing operations |
$ |
1,167,191 |
$ |
894,772 |
|||
Discontinued
operations: |
|||||||
Gain
from operations of discontinued component |
-- |
49,552 |
|||||
Income
tax |
-- |
(
17,343 |
) | ||||
Income
tax benefit |
-- |
17,343 |
|||||
Gain
on discontinued operations |
-- |
49,552 |
|||||
Net
Income |
$ |
1,167,191 |
$ |
944,324 |
|||
Earnings
per share |
|||||||
Net
income: |
|||||||
Basic |
.09 |
.07 |
|||||
Diluted |
.07 |
.06 |
|||||
Weighted
average number of shares outstanding |
13,721,602 |
13,187,217 |
|||||
Weighted
average number of shares adjusted for |
|||||||
dilutive
securities |
16,515,281 |
15,359,284 |
|||||
The
accompanying notes are an integral part of the financial
statements. | |||||||
BOVIE
MEDICAL CORPORATION.
FOR
THE THREE MONTHS ENDED SEPTEMBER 30, 2004 AND 2003
(UNAUDITED) |
|||||||
Third
Quarter |
|||||||
2004 |
2003 |
||||||
Sales |
$ |
5,616,662 |
$ |
4,042,005 |
|||
Cost
of sales |
3,346,904 |
2,285,973 |
|||||
Gross
profit |
2,269,758 |
1,756,032
|
|||||
Costs
and expenses: |
|||||||
Research
and development |
297,291 |
199,983 |
|||||
Professional
services |
84,869 |
92,569 |
|||||
Salaries
and related costs |
439,444 |
396,437 |
|||||
Selling,
general and administrative |
910,572 |
649,816 |
|||||
Equity
in net loss of unconsolidated affiliate |
10,919 |
32,026 |
|||||
1,743,095 |
1,370,831 |
||||||
Gain
(Loss) from operations |
526,663 |
385,201 |
|||||
Other
income (expense): |
|||||||
Interest
|
(3,848 |
) |
(4,613 |
) | |||
Income
|
522,815 |
380,588 |
|||||
Provision
for income tax |
(
194,668 |
) |
(
133,206 |
) | |||
Realized
benefit of loss carryforward |
194,668 |
133,206 |
|||||
Net
income from continuing operations |
$ |
522,815 |
$ |
380,588 |
|||
Discontinued
operations: |
|||||||
Gain
from operations of discontinued component |
-- |
43,032 |
|||||
Income
tax |
-- |
(15,061 |
) | ||||
Income
tax benefit |
-- |
15,061 |
|||||
Gain
on discontinued operations |
-- |
43,032 |
|||||
Net
Income |
$ |
522,815 |
$ |
423,620 |
|||
Earnings
per share |
|||||||
Net
income: |
|||||||
Basic |
.04 |
.03 |
|||||
Diluted |
.03 |
.03 |
|||||
Weighted
average number of shares outstanding |
13,834,101 |
13,115,930 |
|||||
Weighted
average number of shares adjusted for |
|||||||
dilutive
securities |
16,438,199 |
15,512,953 |
|||||
(1)
Certain accounts have been reclassified to conform to current year’s
presentation. | |||||||
The
accompanying notes are an integral part of the financial
statements. |
BOVIE
MEDICAL CORPORATION AND SUBSIDIARIES
INCREASE
(DECREASE) IN CASH AND CASH EQUIVALENTS
FOR
THE NINE MONTHS ENDED SEPTEMBER 30, 2004 AND 2003
(UNAUDITED) |
|||||||
2004 |
2003 |
||||||
Cash
flows from operating activities |
|||||||
Net
income |
$ |
1,167,191 |
$ |
944,324 |
|||
Adjustments
to reconcile net income |
|||||||
to
net cash provided by (used in) operating activities: |
|||||||
Depreciation
and amortization |
295,320 |
211,436 |
|||||
Write
off of patent rights |
-- |
54,790 |
|||||
Write
down fixed assets, |
54,700 |
-- |
|||||
Changes
in current assets and liabilities: |
|||||||
Receivables |
(
296,822 |
) |
(
426,494 |
) | |||
Inventories
and repair parts |
238,321 |
(
161,372 |
) | ||||
Prepaid
expenses |
239,032 |
85,609 |
|||||
Accounts
payable |
90,700 |
165,578 |
|||||
Accrued
expense |
5,043
|
93,611 |
|||||
Other
assets |
-- |
45,044 |
|||||
Obligations
to shareholders |
-- |
(
37,214 |
) | ||||
Customers’
Deposits |
(76,000 |
) |
(
16,000 |
) | |||
Deferred
revenue |
56,109 |
-- |
|||||
Net
cash provided by operating activities |
1,773,594 |
959,312 |
|||||
Cash
flows from investing activities |
|||||||
Fixed
assets |
(571,989 |
) |
(
318,530 |
) | |||
Patents |
(
2,001 |
) |
-- |
||||
Decreased
in deposits |
3,359
|
-- |
|||||
Net
cash used in investing activities |
(570,631 |
) |
(
318,530 |
) | |||
Cash
flows from financing activities |
|||||||
(Decrease)
in notes payable |
(
27,424 |
) |
(531,371 |
) | |||
Common
shares purchased |
289,454 |
88,903 |
|||||
Net
cash provided by (used in) financing activities |
262,030 |
(442,468 |
) | ||||
Net
increase (decrease) in cash and cash equivalents |
1,464,993 |
198,314 |
|||||
Cash
and cash equivalents, beginning of period |
306,137 |
379,209 |
|||||
Cash
and cash equivalents, end of period |
$ |
1,771,130 |
$ |
577,523 |
|||
The
accompanying notes are an integral part of the financial
statements. |
2004 |
2003 |
||||||
Interest
paid |
$ |
13,294 |
$ |
26,210 |
|||
Income
Taxes |
-0- |
-0- |
1) |
Pursuant
to our 2003 executive and employee stock option plan, on April 23, July 1,
and September 23, 2004, we issued 35,000, 50,000, and 225,000 stock
options, respectively, to our directors, certain employees and
consultants. The options are to purchase 310,000 shares at various prices
from $1.30 to $2.95, the bid prices when options were granted. The options
expire 10 years from the dates of issue. |
2) |
During
2004, the Company identified indicators of possible impairment of its
property and equipment. These indicators included the significant decrease
in the market value of equipment compared to new technologies and the
history of cash flows to date. The Company performed an asset impairment
test by comparing the projected undiscounted cash flows to the carrying
cost of the property and equipment. Based on the results of this test, the
Company determined that certain property and equipment with net carrying
cost of $54,700 that was replaced was impaired. The cost of the impaired
equipment was written off. |
1. |
On
September 29, 2003, we issued stock options pursuant to our 2003 executive
and employee stock option plan to directors, certain employees and
consultants to purchase 1,090,000 shares of our common stock at the bid
price of $3.25, the stock price when options were granted. The options
give the recipients the right to purchase the shares for 10 years from the
date of issue. |
2. |
The
Company determined that, based on the results of its operations during
2003, it was appropriate to test its intangible assets for impairment.
Accordingly the Company evaluated the fair value of certain acquired
research and development based on the estimated future cash flows related
to the asset and recorded an impairment charge of $54,790, which has been
included in general and administrative
expenses. |
3. |
In
conjunction with the acquisition of Aaron and the recission offer of 1996,
142,575 shares were issued and contingently held in trust and a
corresponding contingent liability of $18,787 was set up until final
disposition of the actual number of outstanding shares. In 2003, it was
determined that all existing shareholders had converted their shares and
the contingent shares were not necessary. The shares were cancelled and
the additional paid in capital was increased by
$18,787. |
Options |
Preferred |
Common |
Paid-in |
||||||||||||||||||||||
Outstanding |
Shares |
Value |
Shares |
Value |
Capital |
Deficit |
Total |
||||||||||||||||||
Balance
as of |
|||||||||||||||||||||||||
January
1, 2003 |
2,909,000 |
-- |
-- |
13,256,103 |
$ |
13,274 |
$ |
19,820,044 |
$ |
(13,342,067 |
) |
$ |
6,491,251 |
||||||||||||
Subscription
Receivable |
6,131 |
6,131 |
|||||||||||||||||||||||
Cancelled
shares on |
|||||||||||||||||||||||||
Recission
offer |
-- |
-- |
-- |
(142,575 |
) |
(143 |
) |
18,931 |
-- |
18,788 |
|||||||||||||||
Exercise
options for cash |
(350,000 |
) |
350,000 |
3,500 |
247,500 |
-- |
251,000 |
||||||||||||||||||
Options
cancelled or forfeited |
(361,200 |
) |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
||||||||||||||||
Options
granted |
1,791,000 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
|||||||||||||||||
Shares
issued for promotion |
-- |
-- |
-- |
1,000 |
10 |
1,330 |
-- |
1,340 |
|||||||||||||||||
Income
for period |
-- |
-- |
-- |
-- |
-- |
681,317 |
681,317 |
||||||||||||||||||
December
31, 2003 (1) |
3,988,800 |
-- |
-- |
13,464,528 |
$ |
16,641 |
$ |
20,093,936 |
$ |
(12,660,750 |
) |
$ |
7,449,827 |
||||||||||||
(Unaudited) |
|||||||||||||||||||||||||
Exercise
options for cash |
(
167,100 |
) |
-- |
-- |
167,100 |
1,671 |
118,254 |
119,925 |
|||||||||||||||||
Subscription
receivable |
-- |
-- |
-- |
-- |
-- |
1,113 |
1,113 |
||||||||||||||||||
Income
for period |
-- |
-- |
-- |
-- |
-- |
-- |
239,832 |
239,832 |
|||||||||||||||||
March
31, 2004 |
3,821,700 |
-- |
-- |
13,631,628 |
18,312 |
$ |
20,213,303 |
$ |
(12,420,918 |
) |
$ |
7,810,697 |
|||||||||||||
Exercise
options for cash |
(
163,000 |
) |
-- |
-- |
163,000 |
1,630 |
130,870 |
-- |
132,500 |
||||||||||||||||
Subscription
receivable |
-- |
-- |
-- |
-- |
1,595 |
-- |
1,595 |
||||||||||||||||||
Options
granted |
85,000 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
|||||||||||||||||
Options
forfeited |
(10,000 |
) |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
||||||||||||||||
Income
for period |
-- |
-- |
-- |
-- |
-- |
-- |
404,547 |
404,547 |
|||||||||||||||||
June
30, 2004 |
3,733,700 |
-- |
-- |
13,794,628 |
$ |
19,942 |
$ |
20,345,768 |
$ |
(12,016,371 |
) |
$ |
8,349,339 |
||||||||||||
Exercise
options for cash |
(
59,000 |
) |
-- |
-- |
59,000 |
590 |
32,160 |
-- |
32,750 |
||||||||||||||||
Subscription
receivable |
-- |
-- |
-- |
-- |
-- |
1,571 |
-- |
1,571 |
|||||||||||||||||
Options
granted |
225,000 |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
|||||||||||||||||
Income
for period |
-- |
-- |
-- |
-- |
-- |
-- |
522,813 |
522,813 |
|||||||||||||||||
September
30, 2004 |
3,899,700 |
-- |
-- |
13,853,628 |
$ |
20,532 |
$ |
20,379,499 |
$ |
11,493,558 |
$ |
8,906,473 |
|||||||||||||
(1)
The figures for 2003 were derived from the audited financial statements
for that year. | |||||||||||||||||||||||||
The
accompanying notes are an integral part of the financial
statements. |
September
30, 2004 |
December
31, 2003 |
||||||
Raw
materials (net) |
$ |
783,754 |
$ |
1,332,742 |
|||
Work
in process |
733,040 |
616,837 |
|||||
Finished
goods |
488,209 |
501,570 |
|||||
Total |
$ |
2,005,003
|
$ |
2,451,149
|
September
30, 2004 |
December
31, 2003 |
||||||
Raw
Materials |
$ |
317,614 |
$ |
317,614 |
|||
Allowance
for excess or obsolete parts |
(175,411 |
) |
(89,388 |
) | |||
$ |
142,203 |
$ |
228,226 |
1. |
Compensation
costs are recognized as an expense over the period of employment
attributable to any employee stock options.
|
2. |
Stocks
issued in accordance with a plan for past or future services of an
employee are allocated between the expired costs and future costs. Future
costs are charged to the periods in which the services are performed.
|
Nine
months ended September 30 | ||
2004 |
2003 | |
Europe |
49 |
53 |
Asia
|
15 |
12 |
South
America |
11 |
8 |
Canada
|
8 |
5 |
Australia
|
7 |
12 |
Middle
East |
5 |
5 |
Africa
|
3 |
3 |
Other
|
2 |
2 |
Total
|
100% |
100% |
Bovie
Medical Corporation |
(Registrant) |
Date: February
17, 2005 |
/s/Andrew
Makrides |
Chief
Executive Officer - Andrew Makrides |